We thank you for your interest in our company and are pleased to inform you about Boehringer Ingelheim and the progress over the past year. On the one hand, this concerns the Annual Report with the yearly financial statements. On the other hand, we would again like to invite you to find out more about us in the accompanying “ Agility” report.
2017 was a successful year for Boehringer Ingelheim with growth in all businesses. We would like to highlight our human pharmaceuticals business, which showed organic, profitable and distinctly above-market growth.
We are not, however, just looking at sales figures, but rather see them standing for patients with very different medical histories. All of us at Boehringer Ingelheim are motivated by the desire to make an important contribution to the health of people and animals. For generations, Boehringer Ingelheim employees have been researching, developing and manufacturing innovative medicines to positively change the lives of patients. We will invest relatively large sums in the research of new medicines in the future too and have set ourselves the goal, particularly in the human pharmaceuticals business, of 75 per cent of our innovations being the first for patients with the relevant therapeutic approach or mode of action.
The strategic decisions of 2015 and 2016 have laid the foundations for a new period of successful growth for Boehringer Ingelheim. We are thus focused on long-term success.
As in other sectors too, digitisation means sustained change – particularly in data-based industries like ours. With our new BI X lab and through a range of other initiatives, we are facing up to this challenge. We see opportunity here.
We have achieved a great deal over the past year. This success is reflected in the trust our customers have in us, for which we would like to thank them. We would also like to thank our partners, who accompanied and supported us on our journey over the past year. But very special thanks go to each of our employees, who stand for all that we have achieved, who faced new challenges and overcame them with dedication, and who share our passion for making a positive contribution through innovation to the health of people and animals alike.
HUBERTUS VON BAUMBACH